Abstract
To investigate the effects of sulfonylurea receptor 1 (SUR1) exon 33 (TCC-->GCC, S1369A) polymorphism on responsiveness to gliclazide. About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks. SUR1 genotypes were tested by Taqman-PCR. After gliclazide treatment, there was association between T/G polymorphism and decrease of HbA1c. G carriers were more sensitive to gliclazide and the decrease of HbA1c was more significant than TT genotype (TT, 0.76%+/-1.70%; TG+GG, 1.60%+/-1.39%, P=0.044). The polymorphism of SUR1S1369A was associated with the therapeutic efficacy of gliclazide.
Publication types
-
Controlled Clinical Trial
MeSH terms
-
ATP-Binding Cassette Transporters / genetics*
-
Adult
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / genetics
-
Female
-
Genotype
-
Gliclazide / therapeutic use*
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Male
-
Middle Aged
-
Polymorphism, Genetic
-
Potassium Channels / genetics*
-
Potassium Channels, Inwardly Rectifying / genetics*
-
Receptors, Drug / genetics*
-
Sulfonylurea Receptors
Substances
-
ABCC8 protein, human
-
ATP-Binding Cassette Transporters
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Potassium Channels
-
Potassium Channels, Inwardly Rectifying
-
Receptors, Drug
-
Sulfonylurea Receptors
-
hemoglobin A1c protein, human
-
Gliclazide